RDUS - ラディウス・ヘルス （Radius Health Inc.）

Radius Health Inc. (NASDAQ:RDUS) shares, rose in value on Friday, 07/15/22, with the stock price up by 0.20% to the previous day’s close as strong demand from buyers drove the stock to $10.13. Actively observing the price movement in the last trading, the stock closed the session at $10.11, falling within a range of $10.08 … Understanding Radius Health Inc. (NASDAQ: RDUS)’s Growth Potential Read More »

In the last trading session, 1.11 million shares of the Radius Health Inc. (NASDAQ:RDUS) were traded, and its beta was 0.55. Most recently the company’s share price was $10.14, and it changed around -$0.06 or -0.59% from the last close, which brings the market valuation of the company to $475.67M. RDUS currently trades at a … Why Radius Health Inc. (NASDAQ: RDUS) Stock Should Not Be Discarded By Investors In 2022 Read More »

BOSTON, July 07, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) today published a detailed investor presentation available at: https://ir.radiuspharm.com/events-and-presentations/ .

Urges stockholders to vote " FOR " Radius'' highly qualified, independent director nominees – Catherine J. Friedman, Jean-Pierre Garnier, Ph.D. and Andrew C. von Eschenbach, M.D. – on the BLUE proxy card BOSTON, July 07, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (NASDAQ: RDUS ) today published a detailed investor presentation available at: https://ir.radiuspharm.com/events-and-presentations/ . The document discusses the Company''s progress since 2020 and also outlines the comprehensive strategic review process conducted by the Radius Board of Directors, which resulted in its unanimous approval of the Company''s acquisition by Gurnet Point Capital and Patient Square Capital at a significant premium. Stockholders are urged to vote "FOR" all three of the Company''s highly qualified, independent nominees on the BLUE proxy card at its upcoming Annual Meeting of Stockholders, which will be held online on July 26, 2022. YOUR VOTE IS IMPORTANT VOTE "FOR" RADIUS'' THREE NOMINEES ON THE BLUE PROXY CARD TODAY 509 Madison Avenue New York, NY 10022 Email: RDUS@info.morrowsodali.com Call toll-free at (800) 662-5200 (in North America) or +1 (203) 658-9400 (outside of North America) About Radius Radius is a global biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health, neuro- orphan diseases, and oncology.

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Radius Health, Inc. (“Radius” or “the Company”) (NASDAQ: RDUS) for potential breaches of fiduciary duty on the part of its directors and management. If you are a shareholder who has held shares of Radius purchased prior to June 23, 2022, click here to

Radius Health Inc. (NASDAQ:RDUS) shares, rose in value on Friday, 07/15/22, with the stock price up by 0.20% to the previous day’s close as strong demand from buyers drove the stock to $10.13. Actively observing the price movement in the last trading, the stock closed the session at $10.11, falling within a range of $10.08 … Understanding Radius Health Inc. (NASDAQ: RDUS)’s Growth Potential Read More »

In the last trading session, 1.11 million shares of the Radius Health Inc. (NASDAQ:RDUS) were traded, and its beta was 0.55. Most recently the company’s share price was $10.14, and it changed around -$0.06 or -0.59% from the last close, which brings the market valuation of the company to $475.67M. RDUS currently trades at a … Why Radius Health Inc. (NASDAQ: RDUS) Stock Should Not Be Discarded By Investors In 2022 Read More »

BOSTON, July 07, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) today published a detailed investor presentation available at: https://ir.radiuspharm.com/events-and-presentations/ .

Urges stockholders to vote " FOR " Radius'' highly qualified, independent director nominees – Catherine J. Friedman, Jean-Pierre Garnier, Ph.D. and Andrew C. von Eschenbach, M.D. – on the BLUE proxy card BOSTON, July 07, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (NASDAQ: RDUS ) today published a detailed investor presentation available at: https://ir.radiuspharm.com/events-and-presentations/ . The document discusses the Company''s progress since 2020 and also outlines the comprehensive strategic review process conducted by the Radius Board of Directors, which resulted in its unanimous approval of the Company''s acquisition by Gurnet Point Capital and Patient Square Capital at a significant premium. Stockholders are urged to vote "FOR" all three of the Company''s highly qualified, independent nominees on the BLUE proxy card at its upcoming Annual Meeting of Stockholders, which will be held online on July 26, 2022. YOUR VOTE IS IMPORTANT VOTE "FOR" RADIUS'' THREE NOMINEES ON THE BLUE PROXY CARD TODAY 509 Madison Avenue New York, NY 10022 Email: RDUS@info.morrowsodali.com Call toll-free at (800) 662-5200 (in North America) or +1 (203) 658-9400 (outside of North America) About Radius Radius is a global biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health, neuro- orphan diseases, and oncology.

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Radius Health, Inc. (“Radius” or “the Company”) (NASDAQ: RDUS) for potential breaches of fiduciary duty on the part of its directors and management. If you are a shareholder who has held shares of Radius purchased prior to June 23, 2022, click here to

Radius Health Inc. (NASDAQ:RDUS) shares, rose in value on Friday, 07/15/22, with the stock price up by 0.20% to the previous day’s close as strong demand from buyers drove the stock to $10.13. Actively observing the price movement in the last trading, the stock closed the session at $10.11, falling within a range of $10.08 … Understanding Radius Health Inc. (NASDAQ: RDUS)’s Growth Potential Read More »

In the last trading session, 1.11 million shares of the Radius Health Inc. (NASDAQ:RDUS) were traded, and its beta was 0.55. Most recently the company’s share price was $10.14, and it changed around -$0.06 or -0.59% from the last close, which brings the market valuation of the company to $475.67M. RDUS currently trades at a … Why Radius Health Inc. (NASDAQ: RDUS) Stock Should Not Be Discarded By Investors In 2022 Read More »

BOSTON, July 07, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) today published a detailed investor presentation available at: https://ir.radiuspharm.com/events-and-presentations/ .

Urges stockholders to vote " FOR " Radius'' highly qualified, independent director nominees – Catherine J. Friedman, Jean-Pierre Garnier, Ph.D. and Andrew C. von Eschenbach, M.D. – on the BLUE proxy card BOSTON, July 07, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (NASDAQ: RDUS ) today published a detailed investor presentation available at: https://ir.radiuspharm.com/events-and-presentations/ . The document discusses the Company''s progress since 2020 and also outlines the comprehensive strategic review process conducted by the Radius Board of Directors, which resulted in its unanimous approval of the Company''s acquisition by Gurnet Point Capital and Patient Square Capital at a significant premium. Stockholders are urged to vote "FOR" all three of the Company''s highly qualified, independent nominees on the BLUE proxy card at its upcoming Annual Meeting of Stockholders, which will be held online on July 26, 2022. YOUR VOTE IS IMPORTANT VOTE "FOR" RADIUS'' THREE NOMINEES ON THE BLUE PROXY CARD TODAY 509 Madison Avenue New York, NY 10022 Email: RDUS@info.morrowsodali.com Call toll-free at (800) 662-5200 (in North America) or +1 (203) 658-9400 (outside of North America) About Radius Radius is a global biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health, neuro- orphan diseases, and oncology.

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Radius Health, Inc. (“Radius” or “the Company”) (NASDAQ: RDUS) for potential breaches of fiduciary duty on the part of its directors and management. If you are a shareholder who has held shares of Radius purchased prior to June 23, 2022, click here to